Compass Pathways, NeuroKaire enter R&D collaboration

NeuroKaire, a company in precision psychiatry and neurology, has launched an R&D collaboration with Compass Pathways (CMPS). This collaboration aims to deepen the mechanistic understanding of psychedelic compounds by testing the structure of, and connectivity between neurons (brain cells) using patient-derived neurons with known clinical phenotypes. The study will make use of stem cell derived-neurons from individuals with treatment-resistant depression and major depressive disorder. The planned study leverages NeuroKaire’s proprietary platform, which applies cutting edge biology and AI-powered image analysis to see how various compounds affect aspects of communication between the neurons using a proprietary neuroplasticity marker. This provides a unique window into the cellular mechanisms of these potential treatments, and to the differences between them. This collaboration brings NeuroKaire together with a true global innovator. Compass Pathways is at the forefront of mental health innovation, committed to rigorous science and accelerating patient access to new evidence-based treatments.